Precision BioSciences stock rises on early-stage CAR-T trial data [MarketWatch]
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: MarketWatch
Precision BioSciences stock rises on early-stage CAR-T trial data Shares of Precision BioSciences Inc. DTIL, +8.80% are up 13% in premarket trading after it announced positive results from a small Phase 1 clinical trial for its chimeric antigen receptor (CAR) T cell therapy. Precision, which is developing the drug with a not-for-profit French pharmaceutical company Servier, tested the experimental therapy in patients with Non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. "These first-in-human data for PBCAR0191 suggest a tolerable safety profile and encouraging early evidence of clinical activity," Dr. Bijal Shah, an oncologist at the Moffitt Cancer Center in Tampa, Fla., and the trial's clinical investigator, said in a news release. Precision went public earlier this year; its stock is up 144% for the last three months. The S&P 500 SPX, +0.00% has gained 5% during the same period.
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis BBusiness Wire
- Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences to Participate in Upcoming November Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences to Participate in Upcoming November Investor ConferencesBusiness Wire
DTIL
Earnings
- 11/4/24 - Miss
DTIL
Sec Filings
- 11/21/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- DTIL's page on the SEC website